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Abstract. Abnormalities in cerebral glucose metabolism detectable on
fluorodeoxyglucose positron emission tomography (FDG PET) can be
assessed on a regional or voxel-wise basis. In regional analysis, the average
relative uptake over a region of interest is compared with the average
relative uptake obtained for normal controls. Prior knowledge is required
to determine the regions where abnormal uptake is expected, which can
limit its usability. On the other hand, voxel-wise analysis consists of
comparing the metabolic activity of the patient to the normal controls
voxel-by-voxel, usually in a groupwise space. Voxel-based techniques are
limited by the inter-subject morphological and metabolic variability in
the normal population, which can limit their sensitivity.
In this paper, we combine the advantages of both regional and voxel-wise
approaches through the use of subject-specific PET models for glucose
metabolism. By accounting for inter-subject morphological differences,
the proposed method aims to remove confounding variation and increase
the sensitivity of group-wise approaches. The method was applied to a
dataset of 22 individuals: 17 presenting four distinct neurodegenerative
syndromes, and 5 controls. The proposed method more accurately dis-
tinguishes subgroups in this set, and improves the delineation of disease-
specific metabolic patterns.
1 Introduction
In current clinical practice, fluorodeoxyglucose positron emission tomography
(FDG PET) is commonly used to diagnose dementias. FDG uptake reflects glu-
cose consumption, which is reduced by synaptic dysfunction and neuronal de-
generation [1]. Different neurodegenerative diseases affect different areas of the
brain, and localising abnormalities is essential for differential diagnosis [2–4].
Cerebral glucose metabolism as measured by FDG PET can be quantita-
tively evaluated either regionally or on a voxel-by-voxel basis. In regional anal-
ysis, the regional standardised uptake value ratio, defined as the average uptake
in a region of interest (ROI) relative to a reference region (commonly the pons
or cerebellar grey matter), is compared with the regional SUVR expected in a
normal control population. This analysis usually requires prior knowledge re-
garding the selection of relevant discriminant regions, limiting its use [5]. In
voxel-wise analysis, a subject’s PET image is usually aligned to a standardised
group space to compare the metabolic activity of the spatially normalised scan
on a voxel-by-voxel basis to a distribution obtained from normal control scans,
e.g. to produce a Z-score [6]. Exploratory in nature, voxel-wise techniques re-
quire less prior information than regional SUVR analysis, but their sensitivity
is limited by inter-subject variability in non-pathological tracer uptake, making
pathological effects harder to detect [5]. Furthermore, there is theoretical uncer-
tainty regarding how to appropriately resample PET data to the group space,
how to match the PET point spread function with the group-wise model under
linear and non-linear transformations, and how to map the PET data to the
group space in a biologically plausible manner.
In this paper, we combine the advantages of both regional and voxel-wise
approaches by analysing PET data in the original subject space (as in regional
SUVR approaches) while still providing voxel-by-voxel statistics (as in group-
wise approaches). This is achieved through a subject-specific PET model based
on the propagation of morphologically-matched PET scans. The local morpho-
logical matching reduces both the bias and variance of the healthy patient-
specific model, increasing sensitivity.
2 Method
In the following, 4 approaches analysing FDG PET images are explored: a re-
gional analysis based on SUVR (section 2.3), a voxel-wise analysis in a group
space (section 2.4), a voxel-wise analysis in the subject’s space (section 2.5) and
the proposed subject-specific analysis (section 2.6).
2.1 Data
Twenty-two sets of 18F-FDG PET and T1-weighted MRI brain images were
used to evaluate the proposed methodology, here denoted validation dataset.
Of these subjects, 5 were diagnosed with posterior cortical atrophy (PCA), 5
with semantic dementia (SD), 4 with progressive non-fluent aphasia (PNFA),
3 with logopenic progressive aphasia (LPA) and 5 were healthy controls. The
T1-weighted magnetisation-prepared rapid gradient-echo (3.0 T; TE/TR/TI,
2.9 ms/2200 ms/900 ms; voxel size 1.1 × 1.1 × 1.1 mm3) scans were acquired
on a 3T Siemens Magnetom Trio scanner (Siemens Healthcare, Erlangen, Ger-
many). PET images (voxel size 1.95 × 1.95 × 3.27 mm3) were acquired on a GE
Discovery ST PET/CT scanner (GE Healthcare systems, Waukesha, WI) for
20 minutes, 30 minutes after injection of 185 MBq 18F-FDG. The local ethics
committee approved the study and all subjects gave written, informed consent.
To create fully independent healthy population statistics and to demonstrate
the applicability of the proposed patient-specific modelling strategy to multi-site
data, a dataset of 29 healthy controls with T1-weighted MRI and 18F-FDG PET
were selected from the ADNI2 database1. From here on, this dataset is referred
to as the control dataset.
2.2 Data preprocessing
T1 images from the validation dataset were corrected for intensity non-uniformity
following a nonparametric intensity non-uniformity normalisation method [7].
The T1 images from both the validation and control datasets were then par-
cellated into 143 different regions using a multi-atlas propagation and fusion
algorithm implemented in NiftySeg [8]. PET images were intensity normalised
using the mean uptake of the pons [9].
2.3 Regional analysis
Regional analysis consisted of computing the average standardised uptake in a
region of interest to produce a regional SUVR (rSUVR) for each subject inde-
pendently. This value is then compared with those obtained for normal controls
(NC) by its expression as a Z-score, i.e.
ZrSUVR =
rSUVR− µNCrSUVR
σNCrSUVR
, (1)
where µNCrSUVR and σ
NC
rSUVR are the mean and standard deviation of the 29 control
subjects’ rSUVRs.
2.4 Voxel-by-voxel analysis in the group space
For the voxel-by-voxel group-wise analysis, all image pairs from the control and
the validation datasets were mapped to a common space defined through iter-
ative group-wise non-rigid registration of the T1 data [10]. PET images were
brought to the group space by composing the rigid transformations between
paired PET and T1 images and the non-rigid transformation between the native
T1 images and the group space. After resampling, PET images were smoothed
with a Gaussian filter with 5 mm FWHM.
The 22 PET images of the validation dataset were compared with the 29 of
the control dataset by expressing the value at each voxel x as a Z-score
Zgroup-wise(x) =
IG(x)− µNCG (x)
σNCG (x)
, (2)
where IG corresponds to the subject’s PET in the group space, and µNCG and σ
NC
G
are the mean and standard deviation of the 29 subjects of the control dataset in
the group space.
1 Imaging data were provided by the Alzheimer’s disease neuroimaging initiative
(http://adni.loni.ucla.edu/).
2.5 Voxel-wise analysis in the subject’s space
Analysing the subject’s PET image in its native space requires the control
dataset to be transported to the target subject space. To do so, each of the
29 MRI images of the control dataset was deformed to the target image using
an affine followed by a non-rigid registration [11]. The PET images of the con-
trol dataset, pre-aligned to the MRI images, were then mapped using the same
transformation to the subject MRI image. The Z-score between the subject’s
PET and the entire control dataset aligned to the subject is defined as
Znative(x) =
I(x)− µNC(x)
σNC(x)
, (3)
where I corresponds to the subject’s PET image, and µNC and σNC are the
arithmetic mean and standard deviation of the 29 ADNI2 controls mapped into
the native subject space, respectively.
2.6 Proposed voxel-wise subject-specific analysis
This paper proposes a novel analysis framework that consists of creating a
subject-specific healthy PET template. As in the previous approach (section 2.5),
the control dataset is transported into the target subject space. A local image
similarity measure, here the local normalised cross-correlation (LNCC), is then
used to estimate the morphological similarity between the subject’s MRI and the
set of registered MRIs from the control dataset. To generate the subject-specific
PET Z-score parameters, namely the patient-specific healthy-population mean
and standard deviation, the set of registered PETs is locally selected and fused
using a voxel-wise weighting scheme. As in [12], for all of the N control dataset
MRIs propagated to the target subject’s MRI, the LNCC at each voxel is ranked
across all images. This ranking, denoted rn(x) (with x indexing the voxel and n
indexing the propagated MRI) is converted to a weight by applying an exponen-
tial decay function wn(x) = e−βrn(x), with β = 0.5. Here, wn(x) represents the
weight or contribution of subject n at voxel x to the patient specific model. For
each of the N subjects in the control dataset, let the nth mapped PET image
be denoted by Jn. The subject-specific Z-score model parameters (Iµ, Iσ) are
obtained by a spatially varying weighted average
Iµ(x) =
∑N
n=1 wn(x) · Jn(x)∑N
n=1 wn(x)
(4)
Iσ(x) =
√√√√ Nw
Nw − 1
∑N
n=1 wn(x) · (Jn(x)− Iµ(x))2∑N
n=1 wn(x)
(5)
where Nw is the number of non-zero weights. Finally, the subject-specific Z-score
is defined as
Zsubject-specific(x) =
I(x)− Iµ(x)
Iσ(x)
. (6)
3 Validation & Results
The 18F-FDG PET images of the 22 subjects from the validation dataset were
examined using the regional, group-wise, native and proposed subject-specific
analyses. Comparisons were restricted to 8 clinically relevant regions (Figure 1,
top) for the sake of brevity. These regions were selected to represent the ar-
eas where abnormal uptake, compared with controls, is expected for the four
pathologies represented in our dataset:
– a frontal region, comprising the inferior frontal gyrus, precentral gyrus and
anterior insula, was defined as relevant for PNFA subjects [2, 3];
– the anterior temporal region, comprising the hippocampus, amygdala and
temporal pole, was defined as relevant for SD [3];
– the tempoparietal region, comprising the inferior parietal lobule, posterior
middle and superior temporal gyri, was defined as relevant for LPA [3];
– finally, the occipital region, comprising the inferior, middle and superior
occipital gyri, was defined as relevant for PCA [4].
Each hemisphere was analysed separately to account for left/right asymmetry.
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Fig. 1. T1 images overlaid with the selected ROIs (top) and the patient-specific Z-
scores (bottom) for a representative subject of each condition.
3.1 Subject-specific Z-maps
As a first evaluation of the proposed method, we visually assessed the subject-
specific Z-scores. Z-maps obtained for a representative subject of each condition
are displayed in Figure 1 (bottom). A highly negative Z-score (red) indicates
a reduced FDG uptake in the subject relative to the controls. Note that the
Z-scores coincide with the regions where uptake abnormalities are expected for
each pathology, and that the left/right asymmetries observed for the PNFA,
SD, LPA and PCA subjects match the clinical syndromes: PNFA, SD and LPA
subjects are expected to have greater left hypometabolism [3] while a greater
right hypometabolism can be observed on subjects with PCA [4].
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Fig. 2. Displayed above are the average Z-scores obtained for the rSUVR, group-wise,
native and subject-specific methods in each ROI. The white boxes correspond to the
regions where abnormal uptake is expected for each of the four pathologies while the
black boxes indicate the predominant side when asymmetry is expected.
3.2 Z-score comparison in predefined regions-of-interest
The Z-scores obtained from the rSUVR, and average regional Z-scores obtained
using the group-wise, native and proposed subject-specific methods in each ROI
are displayed in Figure 2. We first note that, using the native and subject-specific
methods, the controls have approximately zero Z-scores in all regions, while high
Z-scores are observed in the occipital region with the group-wise method. We
also note that, when using the proposed method, highly negative Z-scores are
observed for each pathology in regions where a reduced uptake is expected when
compared with healthy controls. Moreover, the left/right observed asymmetries
match the clinical syndromes. These highly relevant Z-score results were stable
for all the subjects in each pathological group. The same significance and stability
was not observed in the native or group-wise methods.
A Wilcoxon-Mann-Whitney test was used to assess whether the different
analysis methods were able to differentiate controls and subjects with pathology.
Results showed that the ZrSUVR, Znative and the proposed Zsubject-specific scores
could distinguish controls from each of the pathologies at a 5% significance level.
With the Zgroup-wise score, only controls and PCA subjects were significantly
different. These results suggest an improvement in sensitivity with the ZrSUVR,
Znative and Zsubject-specific scores when compared with the Zgroup-wise score.
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Fig. 3. Z-maps obtained with the different analysis methods for a subject with LPA.
The white ellipses indicate the predominant side where abnormal uptake is expected.
Z-maps obtained for a representative LPA subject with the different analysis
methods are displayed in Figure 3. We observe higher negative Z-scores in the
relevant ROIs with the subject-specific approach than with the other methods.
4 Discussion & Conclusion
In this paper, we analyse 18F-FDG PET data in the original subject space by
providing voxel-wise statistics of normality/abnormality. The subject PET image
is compared using a Z-score to a subject-specific PET model obtained through
the propagation of morphologically-matched PET scans from a control dataset.
We first observed that, when analysing the PET images in the native subject
space, the normal controls have low Z-scores in all regions, which was not always
the case with the other methods (Figure 2). We note that the Z-scores obtained
with the proposed method coincide with the regions where uptake abnormalities
are expected for each of the pathologies studied and respect the left/right asym-
metry (Figures 1 & 2). Finally, it appears that these highly negative Z-score
results are stable across all subjects in each pathological group, which is not the
case with the other methods (Figure 2).
The group-wise analysis seems strongly affected by uncertainties in the group-
wise registration, driven by subjects with a large amount of atrophy (i.e. subjects
with PCA), and the large variations in the normal population. Analysing the
PET data in the native space avoids registering and resampling the subject
PET into the group space. Furthermore, in the subject-specific method, only the
most morphologically similar controls per target are selected to build the model,
which reduces the variance of the normal population used for comparison in the
Z-score, thus increasing the sensitivity. The low Z-scores systematically observed
for the healthy subjects suggest that the subject-specific analysis is less prone
to false positives. Finally, in contrast with rSUVR-based methods, the proposed
analysis is not restricted to predefined regions.
While our method offers greater sensitivity, this is not its only purpose. It
is our hope that, by disentangling the measurement of atrophy and metabolic
decline, our method may provide a greater understanding of neurodegenerative
diseases. Future work will involve validating the method on a larger dataset to
provide more quantitative results.
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